Test Code: CER

EGFR Cancer-Related Gene Screening, 3 Mutations (Plasma)


Test Methodology:

This test is for the detection of exon 19 deletions, exon 20 and 21 substitutions (T790M and L858R respectively) in the epidermal growth factor receptor (EGFR) gene and will provide a qualitative assessment of the mutation status. Results are intended to aid the clinician in identifying patients with NSCLC who may benefit from treatment with IRESSA (gefitinib), when a tissue sample cannot be evaluated.


Specimen Required: 

10ml EDTA Blood



Turnaround Time : 

Maximum to 5 days